Markus Hörer

Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. It also develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Chunilal Nathwani in 2015 and is headquartered in Stevenage, the United Kingdom.

Part of Ascend Gene & Cell Therapies Ltd., Freeline Therapeutics GmbH is a German biotechnology company that focuses on liver directed gene therapies for bleeding disorders and other chronic diseases. The company is based in Planegg, Germany. The company has a pipeline of gene therapies that have the potential to change the lives of people with chronic, debilitating diseases. Freeline has two key enabling platforms critical to realizing AAV gene therapy across its indications\: its proprietary AAV vector platform and its high-performing manufacturing platform. The company was founded in 2015, and the CEOs are Markus Hörer and Karl Christian Heller. Freeline Therapeutics was acquired by Ascend Gene & Cell Therapies Ltd. from Freeline Therapeutics Holdings Plc on February 10, 2023 for $25.83 million.